It has been about a month since the last earnings report for Biogen Inc. (BIIB). Shares have added about 1.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

Steward Partners Investment Advisory LLC lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 31.8% during the 4th quarter, according to its most recent disclosure with the ...

Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the ...

Biogen (NASDAQ:BIIB) shares traded flat in the premarket on Wednesday after the Alzheimer’s drug developer reported better-than-expected Q4 2024 financials while its full-year outlook ...

In a report released yesterday, William Pickering from Bernstein maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the April 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...

BIIB) shares lost a similar percentage, Bernstein analysts argued. While the DCF valuation indicates an undervalued stock, Bernstein thinks that BIIB is valued on a near-term growth outlook ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the April 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...